Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Clin Cancer Res. 2014 Feb 28;20(9):2424–2432. doi: 10.1158/1078-0432.CCR-13-2648

Figure 1. Change in absolute number of unique productive sequences.

Figure 1

A.) Changes reported between baseline and post-tremelimumab samples from 21 patients with melanoma (GA, in black) and from four healthy donors (HD, in grey). B) Normalized TCR V-beta CDR3 repertoire diversity. Analysis comparing baseline and post-tremelimumab PBMC samples. The values were normalized to 1, to show increase and decrease after treatment in a comparable manner.